L
Luca Boni
Researcher at University of Florence
Publications - 167
Citations - 8348
Luca Boni is an academic researcher from University of Florence. The author has contributed to research in topics: Bevacizumab & FOLFOXIRI. The author has an hindex of 38, co-authored 148 publications receiving 7018 citations. Previous affiliations of Luca Boni include University of Parma.
Papers
More filters
Journal ArticleDOI
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,Monica Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D'Amico,Cristina Granetto,Marina Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone +19 more
TL;DR: An updated analysis of the TRIBE study aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups, and assessed the secondary endpoint of overall survival in the main cohort.
Journal ArticleDOI
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis,Chiara Cremolini,Gianluca Masi,Sara Lonardi,Vittorina Zagonel,Lisa Salvatore,Enrico Cortesi,Gianluca Tomasello,Monica Ronzoni,Rosella Spadi,Alberto Zaniboni,Giuseppe Tonini,Angela Buonadonna,Domenico Amoroso,Silvana Chiara,Chiara Carlomagno,Corrado Boni,Giacomo Allegrini,Luca Boni,Alfredo Falcone +19 more
TL;DR: FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus was improved the outcome in patients with metastatic colorectal cancer and increased the incidence of some adverse events.
Journal ArticleDOI
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
Carlo Aschele,Luca Cionini,Sara Lonardi,Carmine Pinto,Stefano Cordio,Gerardo Rosati,Salvatore Artale,Angiolo Tagliagambe,Giovanni Ambrosini,Paola Rosetti,Andrea Bonetti,Maria Emanuela Negru,Maria Chiara Tronconi,Gabriele Luppi,G. Silvano,Domenico Corsi,Anna Maria Bochicchio,Germana Chiaulon,Maurizio Gallo,Luca Boni +19 more
TL;DR: Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response.
Journal ArticleDOI
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
Andrea Ardizzoni,Luca Boni,Marcello Tiseo,Frank V. Fossella,Joan H. Schiller,Marianne Paesmans,Davorin Radosavljevic,Adriano Paccagnella,Petr Zatloukal,Paola Mazzanti,Donald Bisset,Rafael Rosell +11 more
TL;DR: Cisplatin-based third-generation regimens should remain the standard reference for the treatment of selected patients with advanced-stage NSCLC and of those with earlier-stage disease.
Journal ArticleDOI
Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer: A Randomized Trial
Lucia Del Mastro,Luca Boni,Andrea Michelotti,Teresa Gamucci,N. Olmeo,Stefania Gori,Monica Giordano,Ornella Garrone,Paolo Pronzato,Claudia Bighin,Alessia Levaggi,S. Giraudi,Nicola Cresti,Emanuela Magnolfi,Tiziana Scotto,C. Vecchio,Marco Venturini +16 more
TL;DR: The use of triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer reduced the occurrence of chemotherapy-induced early menopause.